Researchers at the Methodist DeBakey Heart & Vascular Center have shown that a simple, inexpensive test can determine whether it is safe to send home a patient who comes to the emergency room with chest pain. "It is imperative to accurately diagnose patients who come to the emergency department with chest pain, " said Dr. John Mahmarian, cardiologist at the Methodist DeBakey Heart & Vascular Center and principal investigator of the study. "Unfortunately, diagnosing chest pain is often expensive and time-consuming. This new data could save millions of health care dollars and countless hours spent waiting on unnecessary tests." Mahmarian's research, which was published online today in the Annals of Emergency Medicine, shows that patients with a coronary artery calcium score of zero can be safely sent home without further cardiac testing.
Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009. Amneal's generic is an AB-rated, therapeutically equivalent alternative to Ultracet® (a licensed trademark of Ortho-McNeil Janssen). U.S. sales of Tramadol/APAP were $61 MM according to June 2009 IMS Health market data. Tramadol/APAP is a centrally-acting analgesic indicated for the short-term management of moderately severe acute pain. The product is designated a controlled substance in some states. Amneal began shipping Tramadol/APAP in 100-, 500- and 1000-count sizes on January 25, 2010.
In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids. The results of the literature review, root causes of the increase in poisoning deaths during this time period, and suggested solutions to this issue were presented at the American Academy of Pain Medicine's 26th Annual Meeting.
Addex Pharmaceuticals / Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. In the first model, ADX71943 reversed complete Freund adjuvant (CFA)- induced reductions in withdrawal thresholds in a dose-related manner, with a minimum statistically significant effective oral dose of 10 mg/kg. In a second model (Formalin test), ADX71943 showed anti-nociceptive effect after oral administration of 3 to 10 mg/kg.
Differences might exist in the amount of pain medicine given to Latino and white children after surgery, found a new, small study in which Latino children received 30 percent less opioid analgesics (morphine or morphine-like drugs) than white children did. During surgery, administration of non-opioid analgesics (such as acetaminophen) and opioid analgesics was similar between Latino and white children, said lead study author Nathalia Jimenez, M.D., of Seattle Children's Hospital. However, the significant difference after surgery suggests that pain treatment in children has some correlation with the patient's ethnicity, according to the authors.
Cara Therapeutics Reports Positive Phase II Data For Novel Peripheral Analgesic In Acute Post-Operative Pain
Cara Therapeutics, Inc. announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy. Subjects were administered a single intravenous infusion of 0.040 mg/kg CR845 or placebo following surgery, upon reporting a moderate-to-severe pain intensity level of 5 to 8 on a 0-10 pain scale. Analgesia was first assessed by pain intensity measurements for up to 8 hours post-infusion or until the patient requested morphine by initiation of patient-controlled analgesia (PCA morphine).